In order to assess these parameters of tumor behavior in vivo in the context of a functional immune system, we turned to cells derived from mouse pancreatic ductal adenocarcinoma driven by KRas and p53 mutations (Hingorani et al., 2005). This evidence concerns the gene TP53 and pancreatic ductal adenocarcinoma.